Embolic compositions

Patent metadata

Field	Value
Publication number	US-2019298388-A1
Application number	US-201916442869-A
Country	US
Kind code	A1
Filing date	Jun 17, 2019
Priority date	Aug 26, 2016
Publication date	Oct 3, 2019
Grant date	—

Abstract

Described herein are compositions comprising, a polymer; a non-physiological solution; and a visualization agent; wherein the polymer is soluble in the non-physiological solution and insoluble at physiological conditions. Methods of preparing the compositions are disclosed as well as methods of using these compositions to treat vascular conditions.

First claim

We claim:

1 . A composition comprising:
a biocompatible polymer; a solvent; and a visualization agent; wherein the biocompatible polymer is soluble in the solvent and insoluble at physiological conditions, and wherein the composition has a viscosity of less than about 15 centistokes.

2 . The composition of claim 1 , wherein the visualization agent is integrated into or associated with the biocompatible polymer.

3 . The composition of claim 2 , wherein the visualization agent is triiodophenol-lactide-glycolide (TIP).

4 . The composition of claim 1 , wherein the physiological conditions include contact with a physiological fluid including blood, urine, saliva, mucous, vaginal fluid, seminal fluid, cerebral spinal fluid, sweat, plasma, bile, stomach acid, intestinal fluids, or a combination thereof.

5 . The composition of claim 4 , wherein the physiological fluid has a pH of about 7.0.

6 . The composition of claim 4 , wherein the physiological fluid has a pH of between about 7.0 and about 7.8.

7 . The composition of claim 1 , wherein the solvent is a water miscible organic solvent.

8 . The composition of claim 1 , wherein the biocompatible polymer comprises an amine and the amine includes an amino group which is about 90% positively charged at a pH of 5 and about 10% positively charged at a pH of 7.

9 . The composition of claim 1 , wherein the biocompatible polymer includes hydroxyethylmethacrylate (HEMA), lactide, glycolide, polyvinyl pyridine (PVP), 1-vinylimidazole, aminoethyl methacrylate (AEMA), 4-vinylpyridine, alkylalkylacrylate, alkylacrylate, acrylate, styrene, polyvinyl alcohol (PVA), acrylamide, ethylene glycol, or combinations thereof.

10 . The composition of claim 1 , wherein the biocompatible polymer includes about 60% w/w HEMA and the visualization agent includes about 40% w/w TIP.

11 . The composition of claim 1 , wherein the biocompatible polymer includes about 15% w/w HEMA and the visualization agent includes about 85% w/w TIP.

12 . The composition of claim 1 , wherein the solvent is water or a co-solvent of water and dimethyl sulfoxide (DMSO).

13 . The composition of claim 1 , further comprising aminopropylmethacrylamide.

14 . The composition of claim 13 , wherein the composition has a viscosity of less than about 14 centistokes.

15 . The composition of claim 1 , wherein the composition has a viscosity of less than about 14 centistokes.

16 . The composition of claim 1 , wherein the biocompatible polymer, together with the visualization agent, forms a cohesive precipitate when insoluble at physiological conditions, and wherein the cohesive precipitate is more cohesive than a precipitate formed from an embolic composition comprising N-butyl-2-cyanoacrylate.

17 . A method of delivering a composition comprising:
injecting the composition of claim 1 through a delivery device into a location with the physiological condition.

18 . A composition comprising:
a precipitating hydrophobic injectable liquid (PHIL) comprising a polymer having a viscosity of less than about 15 centistokes; and a solvent; wherein the PHIL is soluble in the solvent and insoluble at physiological conditions.

19 . The composition of claim 18 , wherein the polymer includes TIP and HEMA.

20 . The composition of claim 18 , wherein the solvent is DMSO.

21 . The composition of claim 18 , wherein the PHIL includes 25% w/w polymer and 75% w/w solvent.

22 . The composition of claim 18 , further comprising a radiopaque compound.

23 . The composition of claim 22 , wherein the radiopaque compound is an iodinated compound, a metal particle, barium sulfate, superparamagnetic iron oxide, gadolinium, tantalum, tungsten carbide, molybdenum, rhenium, or a combination thereof.

24 . The composition of claim 18 , wherein the PHIL is less than about 20% w/w polymer.

25 . A method of delivering a composition comprising:
injecting the composition of claim 18 through a delivery device into a location with the physiological condition.

Assignees

• Microvention Inc

Inventors

• Baldwin Aaron
• Mehta Ami
• Lam Jonathan

Classifications

• A61B2090/3966

  Radiopaque markers visible in an X-ray image · CPC title

• A61B2017/00942

  hydrophilic · CPC title

• C08L33/14

  of esters containing halogen, nitrogen, sulfur, or oxygen atoms in addition to the carboxy oxygen · CPC title

• A61K49/0442

  Polymeric X-ray contrast-enhancing agent comprising a halogenated group · CPC title

• A61K49/0438

  Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol · CPC title